CA
NZ
UK
AU
IND
US
This slight earnings shortfall occurred as the biopharmaceutical company marked its first full quarter of commercial sales for AVLAYAH (tividenofusp alfa-eknm), generating $3.6 million in net product revenue for the Hunter syndrome treatment. This initial AVLAYAH revenue, coupled with strategic financial moves, positions Denali …
Share price moved modestly higher, reflecting market optimism about the upcoming readouts.
Health Catalyst, Inc. (NASDAQ: HCAT) has repaid its debt after selling its Vitalware business for $147 million. The company used the proceeds from the sale, along with cash on hand, to repay its outstanding debt. This move is expected to improve the company's financial …
Roku (NASDAQ: ROKU) delivered a powerful second‑quarter performance, with platform revenue rising 25% year over year to $1.22 billion and earnings per share of $1.18 beating the $0.61 consensus. Total net revenue reached $1.35 billion, up 22% YoY, while net income climbed to $164 …
BioLife Solutions (NASDAQ: BLFS) delivered Q2 earnings per share of $0.04, surpassing the $0.03 consensus figure, while revenue climbed 21% to $28.5 million. GAAP net income surged to $45.1 million, buoyed by a $42.4 million non‑cash tax benefit, and adjusted EBITDA hit $7.4 million, …
Zbtlink's decision to suspend sales of its routers follows alarming reports revealing backdoor vulnerabilities within its devices. This discovery has ignited concerns about user privacy and cybersecurity, particularly at a time when digital security remains paramount. Analysts anticipate that this incident will not only …
Salesforce CEO Marc Benioff asserts that investor fears concerning AI technology threatening the company are "dead wrong," despite a more than 30% fall in CRM stock during 2026. This decline raises concerns among investors regarding the company's future, particularly with Wall Street's apprehension about …
Concentra Group Holdings Parent, Inc. (NYSE: CON) posted second‑quarter earnings per share of $0.52, eclipsing the $0.42 consensus estimate, while revenue climbed 10.0% to $606.0 million. Net income surged 45.7% to $67.3 million, and Adjusted EBITDA rose 22.5% to $140.9 million. Investors gain confidence …
Definium Therapeutics (NASDAQ: DFTX) posted a quarterly earnings per share of $-1.44, sharply missing the $-0.56 consensus estimate, while its cash, cash equivalents and investments climbed to approximately $1.1 billion, more than double the $411.6 million balance at the end of 2025. The cash …
Eli Lilly's second-quarter revenue surged 48% year over year, reaching $23 billion, driven by booming sales of obesity treatments like Mounjaro and Zepbound. This performance prompted the company to raise its full-year revenue guidance to between $85 billion and $87 billion, indicating strong growth …
Please wait processing your request...